| 1林万隆,谷晓媛,倪克襟.肿瘤分子靶向治疗研究现状[J].世界肿瘤杂志,2008,7(3):187-190.
2蒋国棵,洪小南,樊吱,等.吉非替尼治疗手术、放疗、化疗治疗后失败的非小细胞肺癌的初步报告[J].中国肺癌杂志,2004,7(4):305.
3霍伟,冯仲珉,赵卫红,等.吉非替尼治疗晚期非小细胞肺癌64例[J].临床肿瘤学杂志,2005,10(1):4.
4张晓彤,李龙芸,工树兰,等.吉非替尼治疗晚期非小细胞肺癌疗效观察[J].中华结核和呼吸杂志,2005,28(3):180.
5郑迪,山岛忠宏,平岛智德,等.吉非替尼单药治疗化疗失败的晚期非小细胞肺癌31例[J].中国新药杂志,2004,13(6):5
6Clark JW,Eder JP,Ryan D,et al.Safely and pharmacokinetics of the dual action raf kinase and vascular endothelial growth factor receptor inhibitor,BAY43-9006,in patients with advanced refractory solid tumors[J].Clin Cancer Res,2005,11(15):5472-5480.
7Perez-Soler R,Chachoua A,Hammond LA,et al.Determinants of tumor response and survival with erlotinib in patients with none samall-cell lung cancer[J].J Clin Oncol,2004,22(16):3238-3247.
8许晓芹.吉非替尼(易瑞沙)治疗肺癌的护理18例[J].齐齐哈尔医学院学报,2008,29(3):374-375.
9Chu D,Lacouture ME,Fillos T,et al.Risk of hand-foot skin reaction with sor-afenib:a systematic reviewand metaanalysis[J].Acta Oncol,2007,47(2):176-186.
10Blum JL,Jones SE,Budar AU,eta1.Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer[J].J Clon Oncol,1999,17:485-493.
11Abushllaih S,Saad ED,Munsell M,et a1.Incidence and severity of hand—foot syndrome in colorectal cancer patients treated with capecitaine:a singel-institution experience[J].Cancer Invest,2002,20(1):3-l0.
12王涛,汪泽飞.希罗达治疗乳腺癌所致手足综合征的发生规律及临床处理[J].癌症进展杂志,2004,7(2):258-260.
13Cohen EF,Rosen F,Stadler WM,et al.PhaseII trial of ZD1839in recurrent or metastatic squamous cell carcinoma of the head and neck[J].J Clin Oncol,2003,21(10):1980-1987.
14Busam KJ,Capodieti P,Motzer R,et al.Cutaneous side-effects in cancer patients treated with the antiepidermal growth factor receptor antibody C225[J].Br J Dermatol,2001,144(6):1169-1176.
15刘渤,赵洪贞,陈玉华.甲沟炎的治疗与护理[J].齐鲁护理杂志,2004,10(10):742-743.
16Demetri GD,Vanoosterom AT,Garrett CR,et al.Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib:a randomized controlled trial[J].Lancet,2006,368(9544):1329-1338.
17周小平,缪景霞,廖荣荣,等.吉非替尼治疗晚期非小细胞肺癌不良反应的观察及护理[J].中华护理杂志,2005,(4O)11:834-835.
18赵艳梅,王雪梅,张俊霞,等.索拉菲尼引起手、足、乳头刺痛和腹泻[J].药物不良反应杂志,2008,(10)2:136-137.
19秦叔逵,龚新雷.索拉非尼治疗原发性肝癌的研究进展[J].临床肿瘤学杂志,2008,(13)12:1057-1068.
20张碧霓,李秋屏,王喜辉,等.特罗凯分子靶向治疗非小细胞肺癌不良反应的护理[J].护理学杂志,2008,23(3):36-37.
21刘清华,林丽珠.肿瘤分子靶向药物都药理与研究[J].医药服务临床药物治疗杂志,2008,51(50):51.
22Kane RC,Farrell AT,Saber H,et al.Solafenib for the treatment of advanced renal cell carcinoma[J].Clin Cancer Res,2006,12(24):7271-7278.
23Demetri GD,Vanoosterom AT,Blackstein M,et al.PhaseⅢ,multicenter,random-ized,double-blind,placebo-controlled trial of SU11248in petients following fail-ure for metastatic GIST[J].J Clin Oncol(Meeting abstracts),2005,23(16s):S312.
24Escudier B,Szczylik C,Elsen T,etal.Randomized phaseⅢtrial of the raf kinase and VEGFR inhibitor sorafenib(BAY43-9006)in patients with advanced renal cell cancer[J].J Clin Oncol(Meeting abstracts),2005,23(16S):S380.
25李毅.癌症患者化疗副反应的护理[J].当代医学,2009,15(9):104-105.
26Demetri GD,Von-Mehren M,Blanke CD,et al.Efficacity and safety of imtinib mesylate in advanced gastrointestinal stromal tummors[J].N Engl J Med,2002,347(7):472-480. |
